Elite Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Elite Pharmaceuticals, Inc. (ELTP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 90.00 thousand shares for the 12-month period ending 2025-03-31, per its 10-K filed 2025-06-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2025-06-30
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-03-31 was 30.00K shares, a 85.00% decline year-over-year.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2024-12-31 was 0.00 shares.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2024-03-31 was 200.00K shares.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2023-12-31 was 0.00 shares.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 90.00K shares, a 97.77% decline from fiscal 2024.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 4.04M shares.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 750.00K shares, a 900.00% increase from fiscal 2021.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2021 was 75.00K shares, a 91.65% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2025-03-31 | 30.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-30 | 30.00K shares derived: sum of 2 quarters · filed 2025-06-30 | 90.00K shares 10-K · filed 2025-06-30 | ||
| 2024-12-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | 60.00K shares 10-Q · filed 2025-02-13 | |||
| 2024-09-30 | 60.00K shares 10-Q · filed 2024-11-14 | ||||
| 2024-03-31 | 200.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-01 | 200.00K shares derived: sum of 2 quarters · filed 2024-07-01 | 4.04M shares 10-K · filed 2024-07-01 | ||
| 2023-12-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-14 | 3.84M shares 10-Q · filed 2024-02-14 | |||
| 2023-09-30 | 3.84M shares 10-Q · filed 2023-11-14 | ||||
| 2022-03-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-29 | 750.00K shares 10-K · filed 2023-06-29 | |||
| 2021-12-31 | 750.00K shares 10-Q · filed 2022-02-14 | ||||
| 2021-03-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-29 | 15.00K shares derived: sum of 2 quarters · filed 2022-06-29 | 75.00K shares 10-K · filed 2022-06-29 | ||
| 2020-12-31 | 15.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-02-16 | 75.00K shares 10-Q · filed 2021-02-16 | |||
| 2020-09-30 | 60.00K shares 10-Q · filed 2020-11-16 | ||||
| 2020-03-31 | 615.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-14 | 615.00K shares derived: sum of 2 quarters · filed 2021-06-14 | 838.00K shares derived: sum of 3 quarters · filed 2021-06-14 | 898.00K shares 10-K · filed 2021-06-14 | |
| 2019-12-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-10 | 223.00K shares derived: sum of 2 quarters · filed 2020-02-10 | 283.00K shares 10-Q · filed 2020-02-10 | 340.00K shares derived: sum of 4 quarters · filed 2020-06-29 | |
| 2019-09-30 | 223.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-11-12 | 283.00K shares 10-Q · filed 2019-11-12 | 340.00K shares derived: sum of 3 quarters · filed 2020-06-29 | 340.00K shares derived: sum of 4 quarters · filed 2020-06-29 | |
| 2019-06-30 | 60.00K shares 10-Q · filed 2019-08-09 | 117.00K shares derived: sum of 2 quarters · filed 2020-06-29 | 117.00K shares derived: sum of 3 quarters · filed 2020-06-29 | 420.00K shares derived: sum of 4 quarters · filed 2020-06-29 | |
| 2019-03-31 | 57.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-29 | 57.00K shares derived: sum of 2 quarters · filed 2020-06-29 | 360.00K shares derived: sum of 3 quarters · filed 2020-06-29 | 460.00K shares 10-K · filed 2020-06-29 | |
| 2018-12-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-02-11 | 303.00K shares derived: sum of 2 quarters · filed 2019-02-11 | 403.00K shares 10-Q · filed 2019-02-11 | ||
| 2018-09-30 | 303.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-11-09 | 403.00K shares 10-Q · filed 2018-11-09 | |||
| 2018-06-30 | 100.00K shares 10-Q · filed 2018-08-09 | ||||
| 2017-12-31 | 300.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-02-09 | 456.67K shares derived: sum of 2 quarters · filed 2018-02-09 | 516.67K shares 10-Q · filed 2018-02-09 | ||
| 2017-09-30 | 156.67K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-11-09 | 216.67K shares 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | 60.00K shares 10-Q · filed 2017-08-09 | ||||
| 2016-12-31 | 1.01M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-02-09 | 1.91M shares derived: sum of 2 quarters · filed 2017-02-09 | 1.91M shares 10-Q · filed 2017-02-09 | ||
| 2016-09-30 | 900.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-11-09 | 900.00K shares 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | 0.00 shares 10-Q · filed 2016-08-09 | ||||
| 2016-03-31 | 280.00K shares 10-K · filed 2016-06-15 | ||||
| 2015-03-31 | 160.17K shares 10-K · filed 2016-06-15 | ||||
| 2014-03-31 | 1.20M shares 10-K · filed 2016-06-15 | ||||
| 2013-03-31 | -45.00K shares 10-K · filed 2014-06-30 | 45.00K shares 10-K · filed 2013-06-21 | |||
| 2012-03-31 | 58.00K shares 10-K · filed 2013-06-21 |